ABL
Nathalie Schmitt has been working as a Technicien contrôle qualité at ABL Europe since August 2020. Prior to this, Nathalie held the title of technicienne microbiologie at CENTRE D'ANALYSES ET DE RECHERCHES - CAR from July 2012 to July 2020. Nathalie studied at Lycée Jean Rostand from 2010 to 2012 and earned a BTS Bioanalyse et Contrôle, Biologie, général degree.
ABL
From development to market ABL Europe provides GMP viral vectors, contributing to the success of our clients’ immunotherapy innovations. ABL Europe SAS is a pure-play GMP CMO licensed in accordance with EMA, completely dedicated to the provision of viral vector GMP contract manufacturing services, and a subsidiary of ABL Inc. under the corporate ownership of Institut Mérieux. ABL has a strong technical & regulatory track record in process development, scale-up & GMP manufacturing of filterable & non-sterile filterable (aseptic processing) viral vectors used in all phases of clinical development globally. With different adherent platforms (< 60 m2) and suspension (< 500 L) capabilities for drug substance and drug product (< 10,000 vials per batch) in-house, experience in process characterisation and validation, ABL provides its clients with a long-term strategic manufacturing option through clinical development & licensure for a range of virus vector gene therapy & vaccine products. ABL Europe’s clients are located worldwide.